RVTY

WALTHAM, Mass., July 08, 2026--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries. Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20260708774990/en/ Contacts Investor Relations:Steve [email protected] Media Relations: Chet Murray(781) [email protected]

Revvity, Inc. (RVTY) is a life sciences and diagnostics company that develops technologies, software, and services supporting the entire healthcare continuum, from scientific discovery and drug development to disease detection and diagnosis. Its expertise spans translational multi-omics, biomarker identification, imaging, screening, diagnostics, and informatics, helping researchers and healthcare providers advance precision medicine. Revvity generated $2.9 billion in revenue in 2025, employs approximately 11,000 people, and serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across more than 160 countries. Currently carrying a market capitalization of approximately $12.69 billion, Revvity is preparing to report its fiscal 2026 second-quarter results in the near term. SanDisk Slumps 10% But BofA Stays Bullish. Here Is How to Play SanDisk Stock Here. 1 High-Probability Iron Condor Trade on Broadcom Stock to Make Now with 29% Return Potential Nasdaq Futures Slip as Chip Stocks Extend Slide, U.S. Jobs Report in Focus Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Ahead of the release, Wall Street expects the life sciences company to post earnings of $1.23 per share, representing a 4.2% increase from the year-ago quarter. Adding to investor confidence, Revvity has consistently topped analysts' earnings estimates in each of the last four quarters. Looking beyond the upcoming quarter, analysts forecast full-year fiscal 2026 EPS of $5.25, reflecting 3.8% year-over-year growth. Earnings are expected to strengthen further in fiscal 2027, with EPS projected to climb another 10.1% annually to $5.78. Revvity's stock has delivered a relatively steady performance over the past year, although it has trailed the broader market and its sector peers. Shares have gained 12.8% over the past 12 months, lagging the S&P 500 Index's ($SPX) 20.2% return as well as the State Street Health Care Select Sector SPDR ETF's (XLV) 21% gain during the same period. Revvity kicked off fiscal 2026 with a solid first-quarter performance, topping Wall Street's expectations on both revenue and earnings when it reported results on May 5. The health science solutions company generated $711.1 million in quarterly revenue, up 7% year over year, driv...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Revvity (RVTY) is back in focus after announcing plans to divest its China immunodiagnostics business, a unit facing policy and cash flow headwinds, alongside reporting solid first quarter revenue and margin figures. See our latest analysis for Revvity. The stock has given up some ground in the past week, with a 1-day share price decline of 3.94% and a 7-day share price return of 2.14% lower. However, the 90-day share price return is up 8.94% and the 1-year total shareholder return is 6.21%, so momentum has cooled recently after a better run earlier in the year. If this kind of portfolio reshaping has your attention, it can be a good moment to scan the market for other focused growth stories using the 38 healthcare AI stocks With revenue and profit growth holding up, a planned exit from a lower quality unit, and the stock trading at a discount to both an internal value estimate and analyst targets, is this a potential entry point, or is future growth already priced in? Revvity's most followed valuation narrative places fair value at $113.64 compared with the latest close at $98.37, which frames the stock as trading at a meaningful discount and raises a clear question about what is driving that gap. Read the complete narrative. Curious what sits behind that margin reset and fair value call? The narrative leans heavily on steadier revenue growth, higher profits and a richer future earnings multiple, all tied together under a single discounted cash flow view built on an 8.3% discount rate. Result: Fair Value of $113.64 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on China not worsening for Diagnostics and on academic or government funding not softening further, as both could affect revenue and margins. Find out about the key risks to this Revvity narrative. With both risks and rewards in play, does this story align with what you want in your portfolio, or raise more questions to answer quickly? Before making any moves, check the full breakdown of the 2 key rewards and 1 important warning sign. If Revvity has sharpened your thinking, do not stop here. Use focused stock lists to quickly spot other opportunities that fit the way you like to invest. Targe...

A month has gone by since the last earnings report for Revvity (RVTY). Shares have added about 2% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Revvity due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts. Revvity delivered first-quarter 2026 adjusted earnings of $1.06 per share, up 5.0% year over year. The bottom line beat the Zacks Consensus Estimate of $1.02 by 3.9%. Quarterly revenues of $711.1 million increased 7.0% from the year-ago period and topped the consensus mark of $705.2 million by 0.8%. Strong performance across the portfolio helped results beat expectations, with the company reporting 3% organic revenue growth for the quarter and pointing to improving signals in key end markets. RVTY’s growth was supported by contributions from both operating segments. Life Sciences revenues totaled $361.8 million, reflecting year-over-year expansion led by demand in pharma/biotech and academic/government markets. Diagnostics revenues increased to $349.3 million, aided by strength in reproductive health. The company stated better diagnostic trends outside of China, which was partially offset by softer dynamics tied to its China Immunodiagnostics footprint. Revvity reported an adjusted operating margin of 23.6% in the quarter, down 200 basis points year over year. The company attributed the margin pressure to a combination of factors, including ongoing investments, an unfavorable product mix, and the impact of an extra week in the reporting period. Adjusted gross margin was 59.5%, down 220 basis points from the prior-year quarter’s level. Below the operating line, adjusted net interest and other expense totaled $23 million, while the adjusted tax rate was 18.3%, aiding overall adjusted profitability despite the margin contraction. Selling, general and administrative expenses totaled $253.9 million, up 1.7% year over year. Research and development expenses amounted to $57.9 million, up 8% from the year-ago quarter’s reported number. The company exited the first quarter of 2026 with cash and cash equivalents of $860.3 million compared with $919.9 million at the end of the prior quarter. RV...

Revvity, Inc.'s (NYSE:RVTY) stock was strong despite it releasing a soft earnings report last week. We think that investors might be looking at some positive factors beyond the earnings numbers. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Importantly, our data indicates that Revvity's profit was reduced by US$95m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Revvity to produce a higher profit next year, all else being equal. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Because unusual items detracted from Revvity's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Based on this observation, we consider it likely that Revvity's statutory profit actually understates its earnings potential! On the other hand, its EPS actually shrunk in the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example, we've discovered 1 warning sign that you should run your eye over to get a better picture of Revvity. This note has only looked at a single factor that sheds light on the nature of Revvity's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback...

Revvity’s first quarter results were well received by the market, as the company delivered stronger-than-expected organic growth and margins. Management attributed the positive performance to solid execution in both the Life Sciences and Diagnostics segments, with particular momentum in reagents, instruments, and reproductive health. CEO Prahlad Singh highlighted that “the better-than-anticipated revenue and margin performance” reflected resilience across key customer groups, including pharma, biotech, and academic institutions. Strong demand for high-content screening and recent software launches also contributed to the quarter’s results. Is now the time to buy RVTY? Find out in our full research report (it’s free). Revenue: $686.9 million vs analyst estimates of $705.1 million (9.3% year-on-year growth, 2.6% miss) Adjusted EPS: $1.06 vs analyst estimates of $1.01 (4.5% beat) Adjusted EBITDA: $270.1 million vs analyst estimates of $182.5 million (39.3% margin, 48% beat) The company dropped its revenue guidance for the full year to $2.83 billion at the midpoint from $2.98 billion, a 5% decrease Management lowered its full-year Adjusted EPS guidance to $5.25 at the midpoint, a 2.8% decrease Operating Margin: 11.7%, up from 3.2% in the same quarter last year Organic Revenue rose 3% year on year (beat) Market Capitalization: $11.06 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Patrick Donnelly (Citi): Asked about customer engagement and growth cadence in software. CEO Prahlad Singh emphasized strong interest in new AI-powered platforms, while CFO Max Krakowiak explained that tough comparisons will impact near-term growth but expects acceleration later in the year. Puneet Souda (Leerink): Questioned how the China divestiture affects M&A appetite. Singh said Revvity remains acquisitive but will focus capital on high-return opportunities and share buybacks, rather than large-scale deals. Daniel Brennan (TD Cowen): Inquired about drivers of strength in reproductive health and the outlook for the Genomics England contract. Krakowiak highlighted robust instrument placements and assay expansion, noting the business...

Management is divesting the China immunodiagnostics business to exit a market facing persistent policy-induced headwinds, pricing pressures, and structural requirements for localized manufacturing. The divestiture allows for a strategic pivot toward the China Life Sciences segment, which outperformed diagnostics and grew reagents solidly above the prior year's levels. Performance attribution for the quarter was driven by a recovery in pharma and biotech spending, marking the strongest year-over-year growth for reagents and instruments since early 2023. Management highlighted a 'demand bottleneck' in physical validation work as AI accelerates therapeutic discovery, positioning Revvity's wet lab tools as essential for translating computational predictions into biological facts. Internal AI adoption is being utilized to accelerate software delivery and operational efficiency at a fraction of traditional implementation costs, according to third-party research. The company is seeing a divergence from peers in pharma/biotech and academic end markets, which management attributes to a more resilient and specialized product portfolio. Full-year 2026 pro forma organic growth is projected at 3% to 4%, assuming a prudent stance on the sustainability of the pharma and academic recovery. The China divestiture is expected to improve total company organic growth by approximately 100 basis points and enhance operating margins by 30 basis points annually. Management anticipates robust margin expansion in the first half of 2027 as cost-efficiency initiatives, set to be completed by mid-2026, reach their full annualization. Software revenue is expected to face a 20% decline in Q2 due to difficult year-over-year comparisons before returning to high-teens growth in the second half of the year. The company plans to pay off approximately $600 million in Eurobonds due in July, aiming for a gross leverage ratio below 3x by year-end. The planned divestiture of the China immunodiagnostics business represents approximately 6% of total company revenue and was previously a drag on cash flow conversion. A letter of intent has been signed with a management-led buyer group, with a definitive agreement expected within two months and a final close by the end of 2027. The Genomics England contract contributed more than expected to reproductive health growth, though full-year contribution estima...

Revvity, Inc. RVTY delivered first-quarter 2026 adjusted earnings of $1.06 per share, up 5.0% year over year. The bottom line beat the Zacks Consensus Estimate of $1.02 by 3.9%. Quarterly revenues of $711.1 million increased 7.0% from the year-ago period and topped the consensus mark of $705.2 million by 0.8%. Strong performance across the portfolio helped results beat expectations, with the company reporting 3% organic revenue growth for the quarter and pointing to improving signals in key end markets. So far this year, RVTY’s shares have lost 10.6% compared with the industry’s decline of 11.9%. The S&P Index has gained 6.4% in the same period. Image Source: Zacks Investment Research RVTY’s growth was supported by contributions from both operating segments. Life Sciences revenues totaled $361.8 million, reflecting year-over-year expansion led by demand in pharma/biotech and academic/government markets. Diagnostics revenues increased to $349.3 million, aided by strength in reproductive health. The company stated better diagnostic trends outside of China, which was partially offset by softer dynamics tied to its China Immunodiagnostics footprint. Revvity reported an adjusted operating margin of 23.6% in the quarter, down 200 basis points year over year. The company attributed the margin pressure to a combination of factors, including ongoing investments, an unfavorable product mix, and the impact of an extra week in the reporting period. Adjusted gross margin was 59.5%, down 220 basis points from the prior-year quarter’s level. Below the operating line, adjusted net interest and other expense totaled $23 million, while the adjusted tax rate was 18.3%, aiding overall adjusted profitability despite the margin contraction. Selling, general and administrative expenses totaled $253.9 million, up 1.7% year over year. Research and development expenses amounted to $57.9 million, up 8% from the year-ago quarter’s reported number. The company exited the first quarter of 2026 with cash and cash equivalents of $860.3 million compared with $919.9 million at the end of the prior quarter. RVTY generated $115.2 million of net cash provided by operating activities in the quarter compared with $128.2 million in the year-ago period. After capital expenditures of $19.8 million and proceeds from capital disposals, free cash flow was reported at $115 million, with year-to-date fre...

Revvity (RVTY) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +4.10%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.63 per share when it actually produced earnings of $1.7, delivering a surprise of +4.29%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Revvity, which belongs to the Zacks Medical Services industry, posted revenues of $711.12 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.85%. This compares to year-ago revenues of $664.76 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Revvity shares have lost about 10.6% since the beginning of the year versus the S&P 500's gain of 5.2%. While Revvity has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Revvity was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy)...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Revvity, Inc. (RVTY) on Tuesday reported first-quarter earnings of $40.7 million. On a per-share basis, the Waltham, Massachusetts-based company said it had profit of 36 cents. Earnings, adjusted for one-time gains and costs, were $1.06 per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of $1.02 per share. The maker of scientific instruments posted revenue of $711.1 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $705.2 million. Revvity expects full-year revenue in the range of $2.81 billion to $2.84 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RVTY at https://www.zacks.com/ap/RVTY

Revvity (RVTY) reported Q1 adjusted earnings Tuesday of $1.06 per share, up from $1.01 a year earlie

Image source: The Motley Fool. Tuesday, May 5, 2026 at 7:30 a.m. ET President and Chief Executive Officer — Prahlad Singh Chief Financial Officer — Maxwell Krakowiak Vice President, Investor Relations — Stephen Willoughby Prahlad Singh: Thank you, Steve, and good morning, everyone. I have several important developments to discuss today. First, I'm really excited to report that Revvity delivered strong first quarter results with 3% total company organic growth, demonstrating the resilience and strength of our business. Our adjusted operating margins came in at 23.6%, which was above our 23% outlook. These results are a good start to the year and position us well to achieve our full year expectations, which Max will update you on in a bit. The better-than-anticipated revenue and margin performance in the quarter led to our adjusted earnings per share in the quarter being $1.06, which was solidly above the $1.02 to the $1.04 outlook that was implied in our guidance. I next want to highlight a transformative strategic decision we have made that will accelerate our growth trajectory, improve our financial profile and allow for even more focused investments. Following an extensive review, we have decided to divest our immunodiagnostics business in China, which represented approximately 6% of total company revenue last year. This decision reflects our commitment to focusing resources where we can generate the highest returns for shareholders going forward. The health care market in China, particularly diagnostics, has faced persistent policy-induced headwinds that have dramatically impacted both customer demand and pricing dynamics. Unfortunately, we see these challenges continuing over the medium term. To maintain our position in this space, it would require us to make substantial investments, including fully localizing manufacturing, supply chains and regulatory capabilities. This would require meaningful capital allocation, resulting in a deprioritization of other higher potential return initiatives available to us. Rather than deploying material dollars and management attention to address the structural challenges in the China immunodiagnostics market, we are choosing to concentrate our efforts on business areas where we have clear competitive advantages and see healthy growth trajectories. This is an intentional strategic allocation of our resources towards hi...